Skip to main content
KKPCF logo

Kaken Pharmaceutical Co., Ltd. (KKPCF) Stock Price & Analysis

Kaken Pharmaceutical Co., Ltd. (KKPCF) — price $26.00 (0.00%), as of the Nov 19, 2026 trading session; market cap $985M.

Educational signal · not a buy or sell recommendation · How to read this

$26.00 $0.00 (0.00%) Market Cap $985M

Kaken Pharmaceutical Co., Ltd. · KKPCF

Kaken Pharmaceutical Co., Ltd. is a Japanese healthcare company specializing in medical products, devices, and agrochemicals, with a diverse portfolio including treatments for onychomycosis, osteoarthritis, and various skin conditions. The company is actively engaged in R&D, with several products in late-stage clinical trials, alongside its established product lines and a commercial real estate rental business.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • CRON · Cronos Group Inc. · 95 /100
  • COLL · Collegium Pharmaceutical, Inc. · 58 /100
  • HROW · Harrow Health, Inc. · 33 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$26.00
Change on the day0.00%
52-week range$22.30 – $28.12
Market capitalisation$985M
Price / earnings (trailing)15.77
Shares traded on the day2

Price & events

Other perspectives

Council score for Kaken Pharmaceutical Co. (KKPCF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 3, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Negative
Debt/Equity Strong
ROE Neutral
Gross Margin Moderate

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Kaken Pharmaceutical Co. (KKPCF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Kaken Pharmaceutical Co., Ltd. (KKPCF) is the company analyzed here. It employs 1,114 people and is led by Hiroyuki Horiuchi. In Q2 FY2027 it reported revenue of ¥19.01B and net income of -¥444M. The market values it at $985M.

2 · Latest results

What do the latest results show for Kaken Pharmaceutical Co. (KKPCF)?

Short answer · as of

The most recent reported quarter, Q2 FY2027, carried revenue of ¥19.01B. Against analyst estimates the company has EPS beat 0 of the last 3 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2027¥19.01B-¥444M-¥11.71 (diluted)
Q1 FY2027¥29.94B¥8.38B¥221.19 (diluted)
Q4 FY2026¥19.38B¥751M¥19.17 (diluted)
Q3 FY2026¥18.28B¥406M¥10.73 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Kaken Pharmaceutical Co. (KKPCF)?

Short answer · as of

The distress and quality screens read Altman Z 4.77 · Piotroski F 3. Trailing ratios: ROE 6.1% · ROA 4.9% · current ratio 4.17 · earnings yield 6.4%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held KKPCF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported KKPCF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What Investors Ask About Kaken Pharmaceutical Co. (KKPCF)

These answers are editorial: 1 of these 8 answers is drawn from the KKPCF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is KKPCF a good stock to buy?

Stock Expert AI does not rate KKPCF buy, sell or hold. Kaken Pharmaceutical Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the KKPCF stock price today?

The last price recorded for Kaken Pharmaceutical Co., Ltd. (KKPCF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the key considerations for investors regarding Kaken Pharmaceutical Co., Ltd.'s OTC listing?

Investors considering Kaken Pharmaceutical Co., Ltd. should be aware of the implications of its 'OTC Other' market listing. This tier typically involves less stringent reporting requirements compared to major exchanges, and the company's disclosure status is 'Unknown,' which can limit access to timely financial information.

What are the key factors to evaluate for KKPCF?

Evaluate KKPCF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Not financial advice.

How frequently does KKPCF data refresh on this page?

KKPCF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven KKPCF's recent stock price performance?

Kaken Pharmaceutical Co., Ltd. (KKPCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio spanning pharmaceuticals, medical devices, and agrochemicals. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider KKPCF overvalued or undervalued right now?

The trailing P/E of Kaken Pharmaceutical Co., Ltd. (KKPCF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research KKPCF before investing?

Before investing in Kaken Pharmaceutical Co., Ltd. (KKPCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.